We report a retrospective analysis of 38 patients (age ≤ 30 years) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) for relapsed or refractory anaplastic large-cell lymphoma (ALCL). Median follow-up for survivors after undergoing allo-SCT was 72 months (range, 35-96 months). Eight patients received reduced-intensity conditioning (RIC) regimens, including three patients with fludarabine plus melphalan-based regimens and five patients with fludarabine plus busulfan-based regimens. The remaining 30 patients received myeloablative conditioning (MAC) regimens. Median ages in the RIC and MAC groups were 24 and 15 years, respectively. The 5-year overall survival rates in the RIC and MAC groups were 100% and 49%, respectively (P = 0.018). The 5-year event-free survival rates in the RIC and MAC groups were 88% and 43%, respectively (P = 0.039). In the RIC group, four of the eight patients showed residual disease at allo-SCT, but all eight patients survived with complete remission (CR), including one patient with relapse. This result suggests that allo-SCT using the RIC regimen may be effective for relapsed or refractory ALCL in children, adolescents, and young adults, even in non-CR cases.

中文翻译：

---

强度降低的治疗方案的成功结果，然后是异基因造血干细胞移植，用于复发性或难治性间变性大细胞淋巴瘤。

我们报告回顾性分析38例（年龄≤30岁）接受异基因造血干细胞移植（allo-SCT）治疗的复发性或难治性间变性大细胞淋巴瘤（ALCL）。接受异基因SCT后幸存者的中位随访时间为72个月（范围为35-96个月）。8例患者接受了降低强度调理（RIC）方案，包括3例氟达拉滨加美法仑治疗方案的患者和5例氟达拉滨加白消安方案的患者。其余30例患者接受了清髓治疗（MAC）方案。RIC和MAC组的中位年龄分别为24岁和15岁。RIC和MAC组的5年总生存率分别为100％和49％（P = 0.018）。RIC和MAC组的5年无事件生存率分别为88％和43％，分别为（P = 0.039）。在RIC组中，八名患者中有四名在allo-SCT上表现出残留病灶，但八名患者全部存活下来，完全缓解（CR），包括一名复发患者。该结果表明，使用RIC方案的allo-SCT可能对儿童，青少年和年轻人的复发或难治性ALCL有效，即使在非CR病例中也是如此。